A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
Sponsored by Vertex Pharmaceuticals Incorporated
About this study
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Where this study is enrolling
- I'm interested
University of Chicago
Chicago, Illinois
Who can participate
Inclusion criteria
- ✓Clinical history of T1D with \>=5 years of duration of insulin dependence
- ✓At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment
- ✓Stable diabetic treatment
- ✓Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study
Exclusion criteria
- ✕Prior islet cell transplant, organ transplant, or cell therapy
- ✕Other protocol-defined Inclusion/Exclusion criteria may apply
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.